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different risk factors for cardiovascular complications, both in
the general population and in diabetes patients.
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OBJECTIVES: A number of diabetes models have recently been
published. They are often used to assess the cost-effectiveness of
new interventions and to generate health economic arguments
for reimbursement submissions. The majority of these models do
not account for rates of screening for important diabetes-related
microvascular (eye, renal and foot) disease, nor do they consider
the rates of use of important concomitant medications like ACE
inhibitor/angiotensin-2-receptor inhibitors, statins, or aspirin.
Our aim was to test the hypothesis that not accounting for these
important factors may substantially inﬂuence projected long-
term cost-effectiveness of new interventions. METHODS: A
published and validated diabetes model was used to project the
long-term cost-effectiveness of a hypothetical intervention that
lowered HbA1c by 0.4%-points, and which cost an additional
$500/patient/year, versus no intervention. Quality-adjusted life
years (QALY) and lifetime direct medical costs were calculated
for each treatment arm, taking into consideration: A) no screen-
ing for- and appropriate treatment of diabetes-related complica-
tions, or B) screening rates and concomitant medication use as
seen in a typical type-2 diabetes population in the US. RESULTS:
If screening rates and concomitant medication use were not con-
sidered, the hypothetical intervention was dominant to no inter-
vention, with 0.214 QALYs gained (discounted 3% annually),
and discounted lifetime direct cost savings of $165/patient.
When screening rates and concomitant medication rates were
accounted for, the intervention led to smaller improvements 
in QALYs, and increased costs, with incremental costs/QALY
gained of $34,024. CONCLUSIONS: Health economic models
of diabetes must account for the costs and clinical effects of
screening for- and appropriate treatment of important dia-
betic microvascular complications, and the costs and effects of
important concomitant medications. Failure to account for 
these factors may lead to inaccurate assessment of the cost-
effectiveness of new interventions in Type-2 diabetes patients.
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OBJECTIVES: The Economic Assessment of Glycemic control
and Long-term Effects (EAGLE) model version 2.0 simulates
long-term diabetes-related complications and related costs for
type-1 and Type-2 diabetes using equations derived from the
published results of several large interventional studies (DCCT,
WESDR, and UKPDS). To assess the model’s validity, EAGLE
was internally validated according to current guidelines.
METHODS: Following in-house testing protocols, ﬁrst-order
validation identiﬁed inconsistencies in results and corrected 
programming errors. Second-order validation involved the fol-
lowing steps: 1) Simulation sets were created in EAGLE based
on baseline data from the studies used to build the model; 2)
Simulations were run. The results obtained with EAGLE were
compared with the published event rates; and 3) Risk equations
were reﬁned if a deviation of >10% was observed between the
model-derived and published results. Patient numbers and itera-
tions were systematically changed until a ﬁnal run was per-
formed with 50,000 patients and 100 iterations. RESULTS:
Fulﬁlling a criterion for validity, the cumulative incidence per
1000 patient-years and incidence rates for all events simulated
with EAGLE fell within the range of ±10%. The difference
between published data and model results ranged from 0% 
to 9% for all patient populations after possible reﬁnements. 
For example, in Type-2 diabetes, EAGLE successfully predicted
the end-stage renal disease and fatal event rates reported in
UKPDS (deviation = 0%). The rates of severe hypoglycemia dif-
fered by 1%. The EAGLE event rates for proliferative and non-
proliferative retinopathy corresponded well with event rates
derived from the WESDR publications (deviation = 3% and 4%,
respectively). CONCLUSIONS: EAGLE consistently predicts
event rates reported by UKPDS, WESDR, and DCCT, and is thus
a valid and robust tool for the analysis of the long-term diabetes-
related complications and related costs in type-1 and Type-2 
diabetes.
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